John Rogers is expected to take the Deerfield, Illinois-based medical device company’s CFO seat on Oct. 1.

John Rogers, who has experience leading change at companies, is expected to help Baxter’s turnaround gain traction. He joins Baxter after the company sold two business units.

Cooper Companies' 22% three-month surge reflects contact lens share gains, MiSight growth and a recovering fertility business.

Anita Zielinski will join Cardinal Health in November as its new chief accounting officer.

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.

West Pharmaceutical Services has surged 38.1% since March-end as HVP demand, GLP-1 growth and productivity gains fuel the rally.

OMCL raised its 2026 EPS outlook after a strong second quarter, but rising memory-chip costs and delayed hospital purchases could test margins.

In early August 2026, Cardinal Health announced that Anita Zielinski will become Chief Accounting Officer in November, following her interim CFO and senior accounting roles at Baxter and long tenure at Sysco and Ernst & Young, while the company also faced ongoing Class II recalls of subpotent levothyroxine tablets distributed nationwide in the US. This combination of leadership change in Cardinal Health’s finance function and routine but nationwide product recalls comes as analysts are...

Baxter International is back in focus after the fair value estimate in one widely used model moved from US$21.54 to US$27.29, a change of about 27% that feeds directly into updated price target discussions. Analysts are linking this shift to fresh views on earnings execution, segment performance and medium term growth visibility after the latest Q2 results and guidance. As you read on, you will see how to track these changing views and what to watch as the Baxter International story develops...

Baxter International Inc. recently reported past Q2 2026 results, with sales rising to US$2,960 million and quarterly net income increasing to US$126 million compared with the prior year. Alongside this, Baxter raised its 2026 sales growth and adjusted earnings guidance while maintaining a quarterly dividend, signaling management’s confidence in its operating direction. Next, we’ll examine how Baxter’s upgraded 2026 guidance, particularly its higher sales outlook, shapes the company’s...

Baxter International (NYSE:BAX) reported second-quarter 2026 results that exceeded its expectations, supported by broad-based sales growth, strong demand in Advanced Surgery and drug compounding, and a $75 million tariff refund. The company raised its full-year organic sales-growth outlook and incre

The company's second-quarter performance was impressive.

Baxter International has significantly underperformed the broader market over the past year, although analysts remain neutral amid improving fundamentals and recovery prospects.

Shares of healthcare company Baxter International (NYSE:BAX) jumped 8.7% in the afternoon session after the company reported second-quarter results that beat analyst expectations on the top and bottom lines and raised its full-year financial forecast.

Baxter International Inc (BAX) delivered a 5% organic revenue beat in Q2 2026, driven by broad-based growth, but adjusted EPS fell 5% year-over-year due to cost headwinds.

Baxter beats second-quarter earnings and revenue estimates, posts broad-based segment growth and raises its 2026 outlook despite margin pressure.

Baxter’s profits rose 5% in Q2 versus the same period in 2025 that was impacted by factors including hurricane damage to a key facility in North Carolina.

The headline numbers for Baxter (BAX) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Healthcare company Baxter International (NYSE:BAX) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 5.3% year on year to $2.96 billion. Its non-GAAP profit of $0.56 per share was 52.5% above analysts’ consensus estimates.

Baxter (BAX) delivered earnings and revenue surprises of +55.56% and +5.95%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Healthcare company Baxter International (NYSE:BAX) will be reporting results this Thursday before market open. Here’s what you need to know.

Medical product makers face Q2 margin pressure from tariffs and inflation even as demand stays strong. See which earnings reports could surprise.

Baxter International stock has delivered a steep decline of about 64.6% over the past five years, yet current valuation checks suggest the shares may now be trading below an estimate of intrinsic value. With both the Discounted Cash Flow (DCF) intrinsic value estimate and market multiples screening the stock as undervalued, investors are weighing whether this signals an opportunity or a value trap. Baxter International is down roughly 64.6% over five years, which puts recent share price...

Shares of healthcare company Baxter International (NYSE:BAX) jumped 3.6% in the afternoon session after TD Cowen raised its price target on the stock to $24 from $20. The firm maintained its hold rating on the shares, which suggests the analyst recommends neither buying nor selling the stock at its current price. However, the increased price target indicates a more positive valuation outlook for the company than before. The move from the investment firm comes as Baxter holds an average rating of

Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.

BAX's second-quarter results may reflect pressured earnings and sales as manufacturing inefficiencies, inflation, and product holds offset steady demand across segments.

Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.

Baxter trades at $22.13 and has moved in lockstep with the market. Its shares have returned 10% over the last six months while the S&P 500 has gained 8.7%.

Abbott’s (ABT) latest financial disclosure reveals a significant strategic evolution that market participants often overlook amidst the focus on quarterly beats. The company is actively executing a structural pivot, shifting its capital allocation and growth dependency away from the volatile Nutrition segment toward high-margin, innovation-led MedTech and specialized diagnostics.

AbbVie and Baxter both flashed the same bullish technical signal this month, but one golden cross signals genuine momentum while the other masks a fundamentally broken business. Knowing which is which could protect your retirement income from a costly mistake.

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.